Jennison Associates LLC Buys New Holdings in Tyra Biosciences, Inc. $TYRA

Jennison Associates LLC bought a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 632,432 shares of the company’s stock, valued at approximately $24,222,000.

A number of other institutional investors have also recently bought and sold shares of TYRA. Hilton Head Capital Partners LLC acquired a new position in shares of Tyra Biosciences in the 1st quarter valued at $30,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Tyra Biosciences during the 4th quarter worth about $51,000. Chung Wu Investment Group LLC acquired a new stake in shares of Tyra Biosciences during the 4th quarter valued at about $53,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Tyra Biosciences by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after acquiring an additional 534 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in Tyra Biosciences in the first quarter valued at about $276,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Trading Down 3.3%

NASDAQ:TYRA opened at $31.06 on Tuesday. Tyra Biosciences, Inc. has a 1 year low of $9.96 and a 1 year high of $40.65. The firm has a 50 day moving average of $31.10 and a 200-day moving average of $32.47. The stock has a market capitalization of $1.85 billion, a P/E ratio of -14.25 and a beta of 0.76.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). As a group, analysts forecast that Tyra Biosciences, Inc. will post -2.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TYRA has been the subject of several recent research reports. Wolfe Research started coverage on shares of Tyra Biosciences in a research report on Tuesday, May 19th. They issued a “peer perform” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday. JonesTrading initiated coverage on Tyra Biosciences in a report on Wednesday, June 17th. They issued a “buy” rating and a $56.00 target price for the company. Canaccord Genuity Group initiated coverage on Tyra Biosciences in a research report on Monday, April 6th. They set a “buy” rating and a $50.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and issued a $45.00 target price on shares of Tyra Biosciences in a research note on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Tyra Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $47.00.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.